What is the recommended treatment regimen for a patient with chronic hepatitis C virus genotype 2 infection without decompensated cirrhosis?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 15, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Treatment for Chronic Hepatitis C Genotype 2 Without Decompensated Cirrhosis

For patients with chronic HCV genotype 2 infection without decompensated cirrhosis, the preferred first-line regimens are sofosbuvir/velpatasvir for 12 weeks or glecaprevir/pibrentasvir for 8 weeks (without cirrhosis) or 12 weeks (with compensated cirrhosis), both achieving near-perfect cure rates of 99-100%. 1

Treatment Algorithm by Clinical Scenario

Treatment-Naïve Patients WITHOUT Cirrhosis

First-line options (choose one):

  • Glecaprevir/pibrentasvir: 8 weeks (A1 recommendation) 1
    • SVR rate: 99-100% 1
  • Sofosbuvir/velpatasvir: 12 weeks (A1 recommendation) 1
    • SVR rate: 99-100% 1

Alternative options:

  • Sofosbuvir + weight-based ribavirin: 12 weeks (A1 recommendation) 1
    • Ribavirin dosing: 1,000 mg if <75 kg; 1,200 mg if ≥75 kg
  • Daclatasvir + sofosbuvir: 12 weeks (B1 recommendation) 1

Treatment-Naïve Patients WITH Compensated Cirrhosis (Child-Pugh A)

First-line options (choose one):

  • Glecaprevir/pibrentasvir: 12 weeks (A1 recommendation) 1
    • SVR rate: 100% in cirrhotic patients 1
  • Sofosbuvir/velpatasvir: 12 weeks (A1 recommendation) 1
    • SVR rate: 100% in cirrhotic patients 1

Alternative options:

  • Sofosbuvir + weight-based ribavirin: 16 weeks (B1 recommendation) 1
  • Daclatasvir + sofosbuvir: 12 weeks (B1 recommendation) 1

Treatment-Experienced Patients WITHOUT Cirrhosis

First-line options (choose one):

  • Glecaprevir/pibrentasvir: 8 weeks (A1 recommendation) 1
  • Sofosbuvir/velpatasvir: 12 weeks (A1 recommendation) 1
    • SVR rate: 100% in treatment-experienced patients 1

Alternative options:

  • Sofosbuvir + weight-based ribavirin: 12 weeks (A1 recommendation) 1
  • Daclatasvir + sofosbuvir: 12 weeks (B1 recommendation) 1

Treatment-Experienced Patients WITH Compensated Cirrhosis

First-line options (choose one):

  • Glecaprevir/pibrentasvir: 12 weeks (A1 recommendation) 1
  • Sofosbuvir/velpatasvir: 12 weeks (A1 recommendation) 1

Alternative options:

  • Sofosbuvir + weight-based ribavirin: 16-24 weeks (B1 recommendation) 1
    • Extended duration recommended due to both treatment failure history and cirrhosis being adverse factors 2
  • Daclatasvir + sofosbuvir: 12 weeks (B1 recommendation) 1

Key Clinical Considerations

Why these regimens are superior:

The 2018 KASL guidelines 1 represent the most recent high-quality evidence and demonstrate that pangenotypic NS5A/NS5B inhibitor combinations (sofosbuvir/velpatasvir and glecaprevir/pibrentasvir) achieve the highest SVR rates with excellent safety profiles. These regimens outperform the older sofosbuvir + ribavirin combination, which achieved only 94% SVR in comparative trials 1.

Practical advantages of preferred regimens:

  • Glecaprevir/pibrentasvir: Shorter duration (8 weeks for non-cirrhotics), ribavirin-free, single daily tablet
  • Sofosbuvir/velpatasvir: Pangenotypic coverage, ribavirin-free, excellent tolerability, single daily tablet

When to use ribavirin-containing regimens:

Sofosbuvir + ribavirin remains acceptable when newer agents are unavailable or unaffordable 1. However, ribavirin adds toxicity (anemia requiring dose reduction in ~22% of patients 3) without improving outcomes compared to pangenotypic DAA combinations.

Common pitfalls to avoid:

  1. Don't extend treatment unnecessarily: While older guidelines suggested 16-24 weeks for cirrhotic treatment-experienced patients on sofosbuvir + ribavirin 2, the newer pangenotypic regimens achieve 100% SVR with just 12 weeks even in this difficult-to-treat population 1

  2. Don't use peginterferon-based regimens: These are outdated and inferior to DAA-only regimens 1

  3. Monitor for ribavirin-related anemia: If using ribavirin-containing regimens, expect hemoglobin drops averaging 3.0 g/dL, requiring dose reduction in approximately 20% of patients 3

  4. Genotype 2 subtype doesn't matter: Treatment is the same for 2a, 2b, or other subtypes 1

Safety profile:

All recommended DAA regimens demonstrate excellent tolerability. The most common adverse events are mild: fatigue (14-23%), headache (13-23%), and nausea (13%) 1, 4. Serious adverse events and treatment discontinuations are rare (<1%) 4, 5. Real-world data confirms these safety profiles across diverse populations including elderly patients and those with compensated cirrhosis 6, 7, 3.

References

2
Guideline

kasl clinical practice guidelines: management of hepatitis c.

Clinical and Molecular Hepatology, 2016

3
Research

Combination treatment with sofosbuvir and ribavirin for patients diagnosed with hepatitis C genotype 2: A real-world, single-center study.

Arab journal of gastroenterology : the official publication of the Pan-Arab Association of Gastroenterology, 2021

6
Research

Ledipasvir and sofosbuvir for 12 weeks for hepatitis C virus genotype 2 infection: A propensity score matched analysis.

Hepatology research : the official journal of the Japan Society of Hepatology, 2020

Related Questions

What is the appropriate treatment regimen for chronic hepatitis C genotype 2?
What is the recommended treatment for hepatitis C genotype 2?
When should chronic hepatitis C infection be treated?
In a patient with active hepatitis C and a history of hepatitis B, should entecavir be used for hepatitis B prophylaxis without initiating Epclusa (sofosbuvir/velpatasvir) for hepatitis C?
What is the recommended initial treatment regimen for a treatment‑naïve adult with hepatitis C virus infection, no decompensated cirrhosis, and creatinine clearance greater than 30 mL/min?
What medication changes are recommended for a 71-year-old male with early‑onset dementia, benign prostatic hyperplasia, depression, and insomnia who is taking acetaminophen (Tylenol) 650 mg twice daily, ramelteon 8 mg at bedtime, mirtazapine 15 mg at bedtime, lorazepam (Ativan) 0.5 mg twice daily plus 0.5 mg as needed twice daily, donepezil 10 mg at bedtime, and buspirone (Buspar) 7.5 mg twice daily, now exhibiting increased emotional outbursts, crying, yelling, agitation, and aggression toward staff?
Is concurrent use of clopidogrel and aspirin appropriate for coronary artery disease (CAD) prevention?
What is the recommended treatment for hepatitis C genotype 2?
Is guaifenesin an expectorant?
Can a person be infected with hepatitis C more than once?
In a middle‑aged woman with a history of left breast cancer (mastectomy 5 years ago, on tamoxifen 25 mg daily), chronic right‑hip pain for 2–3 years, refractory right‑hip bursitis, lumbar L3‑L4 disc bulge with severe right foraminal stenosis and L4‑L5 mild‑moderate stenosis, who has tried a corticosteroid injection, physical therapy, and ibuprofen 600 mg twice daily, what treatment options are recommended?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.